Disruption of balance of oxidative stress-associated angiogenesis in heart failure by Matos, A et al.
DISRUPTION OF BALANCE OF OXIDATIVE STRESS-ASSOCIATED ANGIOGENESIS IN HEART FAILURE
Andreia Matos1,2, Mário Teixeira Barbosa3, Manuel Pires Bicho1,2, Luiz Menezes Falcão3,4
1 Genetics Laboratory and Environmental Health Institute-ISAMB, Faculty of Medicine, University of Lisbon, Portugal; 2 Instituto de Investigação Científica Bento da Rocha Cabral; 
3Department of Internal Medicine, Hospital Lusíadas Lisboa, Lisbon, Portugal; 4 Faculty of Medicine, University of Lisbon; 5 Department of Internal Medicine, Santa Maria Hospital, 
Lisbon, Portugal.
OBJECTIVE: We investigated the role of sFlit/VEGFR1 and EPO biomarkers in heart failure (HF) patients.
BACKGROUND: Hypoxia may be a concomitant state in heart failure
patient, inducing the disruption of balance of oxidative stress-
associated angiogenesis. Soluble fms-like tyrosine kinase-1 (sFlt-1 or
VEGFR1) and erythropoietin (EPO) activates neovascularization and
reduces apoptosis.
PARTNERSHIPS 
 
 
 
 
 
 
 
 
 
 
 
N=59 HF patients
Mean age: 80.66 (SD 10.78)
RESULTS
METHODS: In total of 59 hospitalized patients with acute decompensate heart failure in class II or IV of NYHA were assessed the
biomarkers of sFlt-1 and EPO. These biomarkers were determined by ELISA. Subgroup analysis was performed according to the
left ventricular ejection fraction in light of the current European Society of cardiology guidelines. Mann-Whitney test, Spearman
correlation and ANCOVA analysis were applied. Statistical significance was considered for P<0.05.
CONCLUSION:
In our study, higher levels of sFlt-1/sVEGFR1 were found in patients with HFrEF, which may untangle a
possible role of hypoxia status in the angiogenic profile of heart failure patients.
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and those of VEGF, hypoxia-inducible factor (HIF), Fas and
leptin (Figure 2) as well as angiotensinogen and cytokines such
as TNF-a and IL-10.
ACVR2A located on chromosome 2q22 and STOX1 on
chromosome 10q22 are two of the first PE susceptibility genes
identified within confirmed regions with significant genome-
wide linkage, and both involving normal variations single
nucleotide polymorphisms [7]. STOX1 Y153H common poly-
morphism and transmission of the maternal susceptibility
allele have been observed in families where several generations
of women exhibited familial severe early-onset PE. STOX1
encodes a transcription factor and has been linked to tropho-
blast dysfunction and IUGR [7]. Interestingly, STOX1 overex-
pression in choriocarcinoma cells mimics the transcriptional
consequences of PE in the human placenta [8,9]. Also, wild-
type female mice crossed with transgenic male mice overex-
pressing human STOX1 gene show characteristics of PE
including HTN, proteinuria, and increased plasma levels of
soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble
endoglin (sEng) [10].
Subjects carrying the T allele VEGF 936C/T genotype have
lower plasma VEGF levels than subjects carrying the VEGF
936C/C genotype. Changes in VEGF gene and plasma levels
could play a role in the vascular endotheliosis associated with
PE [11].
HIF-1a and -2a proteins and regulated genes are increased
in PE placenta. Upregulation of placental HIF-1a may
induce the expression of sFlt-1 and sEng, which are secreted
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Figure 1. Risk factors and pathogenesis of preeclampsia. Genetic and immune factors cause shallow placentation and reduced
uteroplacental perfusion pressure during late pregnancy and trigger the release of circulating bioactive factors. Bioactive
factors could affect the systemic blood vessels and lead to generalized vasoconstriction, increased vascular resistance and
hypertension, or cause increased vascular permeability and edema. The bioactive factors could injure the kidney leading to
increased plasma volume and severe hypertension, as well as glomerular endotheliosis and proteinuria. Increased cerebral
vascular permeability and edema lead to seizures and life-threatening eclampsia. Endotheliosis of the hepatic vessels could
lead to activation of coagulation pathways and manifest as the HELLP syndrome.
GFR: Glomerular filtration rate; RAS: Renin Angiotensin System.
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• Mean ejection fraction was 48.45±17.68%
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HFmEF 40-49%
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r=0.856, P=0.034
